An Investigation Into the Feasibility of Beetroot Juice Supplementation in People Living With Alzheimer's Disease.

Summary

The goal of this clinical trial is to learn if taking a beetroot juice supplement will work in people living with Alzheimer's disease. The main questions it aims to answer are: * Can people living with Alzheimer's disease realistically drink beetroot juice regularly (for example, is it easy to take, free from side effects and acceptable)? * Does drinking beetroot juice twice a day improve health in people living with Alzheimer's disease? Researchers will look at how you managed with the beetroot juice, as well as if there were any improvements in your health measures. Participants will: * Complete testing before and after the intervention for no more than 3 hours each time * Complete a 1-day food diary before testing * Take a beetroot juice supplementation twice daily for 1-week * Keep a note of any problems with the beetroot juice

Interventions

• Beetroot juice · DIETARY_SUPPLEMENT

  Participants will take a concentrated beetroot juice shot (70ml) twice daily for 1-week. Each shot contains 400mg of dietary nitrate (800mg per day).

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Aged 65-85 years
* Mild or Moderate Alzheimer's disease
* Participants must be able to speak, read, and understand English to participate in this study.
* To support adherence, participants are asked to have a carer, partner, friend, or family member available to assist with reminders to take the shots twice daily.

Exclusion Criteria:

* Advanced or severe Alzheimer's Disease
* Diagnosis of an additional neurological condition
* Have used antibiotics in the last month
* Use of mouthwash in the last month
* Use of medication affecting nitrate metabolism (for example proton pump inhibitors, Isosorbide Mononitrate, Sildenafil or Glyceryl Trinitrate).
* Unable to provide informed consent
* Allergies to beetroot
* Taking part in pharmacological trials

Sites (1)

• University of the West of Scotland, Glasgow, Lanarkshire